Hims & Hers Health (NYSE:HIMS) posts Q3 2026 sales in line with estimates but full-year sales guidance misses expectations
Hims & Hers Health (NYSE:HIMS) posts Q3 2026 sales in line with estimates but full-year sales guidance misses expectations TradingView
Covered in this story
Analyst targets on Hims Hers Health Inc Class a
- Truist Securities: at $28.5 · target $32 by Oct 2027 · Hold via Investing.com
“At” is the closing price nearest the day the target was reported, the price we score it from; it is not an earlier target. Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $HIMS yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Hims Hers Health Inc Class a →Summary aggregated from TradingView's public RSS feed. The full reporting belongs to TradingView — please read it on their site.